Back
Speaker illustration

undefined undefined undefined

Presentations

Evaluation of appropriate use and clinical outcomes of idarucizumab as antidote of dabigatran in daily clinical practice

Event: ESC Congress 2018

Topic: Oral Anticoagulation

Session: Atrial fibrillation - Stroke prevention

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources